Global Biosimilar and Biologics Market Growth 2026-2032
The global Biosimilar and Biologics market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
United States market for Biosimilar and Biologics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Biosimilar and Biologics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Biosimilar and Biologics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Biosimilar and Biologics players cover Pfizer, Roche AG, AbbVie, Novartis AG, Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Biosimilar and Biologics Industry Forecast? looks at past sales and reviews total world Biosimilar and Biologics sales in 2025, providing a comprehensive analysis by region and market sector of projected Biosimilar and Biologics sales for 2026 through 2032. With Biosimilar and Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar and Biologics industry.
This Insight Report provides a comprehensive analysis of the global Biosimilar and Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar and Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Biosimilar and Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar and Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar and Biologics.
This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar and Biologics market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
United States market for Biosimilar and Biologics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Biosimilar and Biologics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Biosimilar and Biologics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Biosimilar and Biologics players cover Pfizer, Roche AG, AbbVie, Novartis AG, Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Biosimilar and Biologics Industry Forecast? looks at past sales and reviews total world Biosimilar and Biologics sales in 2025, providing a comprehensive analysis by region and market sector of projected Biosimilar and Biologics sales for 2026 through 2032. With Biosimilar and Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar and Biologics industry.
This Insight Report provides a comprehensive analysis of the global Biosimilar and Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar and Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Biosimilar and Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar and Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar and Biologics.
This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar and Biologics market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Monoclonal Antibody
- Vaccines
- Recombinant Insulin
- Growth Factors
- Immune Modulators
- Fusion Protein
- Erythoprotein
- Other
- Autoimmune Diseases
- Infectious Diseases
- Cardiovascular Disorders
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Roche AG
- AbbVie
- Novartis AG
- Merck
- Bristol Myers Squibb
- GSK
- AstraZeneca
- Eli Lilly
- Bayer
- Gilead Sciences
- Amgen
- Boehringer Ingelheim
- Novo Nordisk
- Viatris
- Johnson
- Sanofi Winthrop Industries
- Serum Institute of India
- Biocon
- Intas Pharmaceuticals
- What is the 10-year outlook for the global Biosimilar and Biologics market?
- What factors are driving Biosimilar and Biologics market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Biosimilar and Biologics market opportunities vary by end market size?
- How does Biosimilar and Biologics break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Biosimilar and Biologics Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Biosimilar and Biologics by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Biosimilar and Biologics by Country/Region, 2021, 2025 & 2032
2.2 Biosimilar and Biologics Segment by Type
2.2.1 Monoclonal Antibody
2.2.2 Vaccines
2.2.3 Recombinant Insulin
2.2.4 Growth Factors
2.2.5 Immune Modulators
2.2.6 Fusion Protein
2.2.7 Erythoprotein
2.2.8 Other
2.2.9 Biosimilar and Biologics Sales by Type
2.2.9.1 Global Biosimilar and Biologics Sales Market Share by Type (2021-2026)
2.2.9.2 Global Biosimilar and Biologics Revenue and Market Share by Type (2021-2026)
2.2.9.3 Global Biosimilar and Biologics Sale Price by Type (2021-2026)
2.3 Biosimilar and Biologics Segment by Application
2.3.1 Autoimmune Diseases
2.3.2 Infectious Diseases
2.3.3 Cardiovascular Disorders
2.3.4 Other
2.3.5 Biosimilar and Biologics Sales by Application
2.3.5.1 Global Biosimilar and Biologics Sale Market Share by Application (2021-2026)
2.3.5.2 Global Biosimilar and Biologics Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Biosimilar and Biologics Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Biosimilar and Biologics Breakdown Data by Company
3.1.1 Global Biosimilar and Biologics Annual Sales by Company (2021-2026)
3.1.2 Global Biosimilar and Biologics Sales Market Share by Company (2021-2026)
3.2 Global Biosimilar and Biologics Annual Revenue by Company (2021-2026)
3.2.1 Global Biosimilar and Biologics Revenue by Company (2021-2026)
3.2.2 Global Biosimilar and Biologics Revenue Market Share by Company (2021-2026)
3.3 Global Biosimilar and Biologics Sale Price by Company
3.4 Key Manufacturers Biosimilar and Biologics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biosimilar and Biologics Product Location Distribution
3.4.2 Players Biosimilar and Biologics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BIOSIMILAR AND BIOLOGICS BY GEOGRAPHIC REGION
4.1 World Historic Biosimilar and Biologics Market Size by Geographic Region (2021-2026)
4.1.1 Global Biosimilar and Biologics Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Biosimilar and Biologics Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Biosimilar and Biologics Market Size by Country/Region (2021-2026)
4.2.1 Global Biosimilar and Biologics Annual Sales by Country/Region (2021-2026)
4.2.2 Global Biosimilar and Biologics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Biosimilar and Biologics Sales Growth
4.4 APAC Biosimilar and Biologics Sales Growth
4.5 Europe Biosimilar and Biologics Sales Growth
4.6 Middle East & Africa Biosimilar and Biologics Sales Growth
5 AMERICAS
5.1 Americas Biosimilar and Biologics Sales by Country
5.1.1 Americas Biosimilar and Biologics Sales by Country (2021-2026)
5.1.2 Americas Biosimilar and Biologics Revenue by Country (2021-2026)
5.2 Americas Biosimilar and Biologics Sales by Type (2021-2026)
5.3 Americas Biosimilar and Biologics Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biosimilar and Biologics Sales by Region
6.1.1 APAC Biosimilar and Biologics Sales by Region (2021-2026)
6.1.2 APAC Biosimilar and Biologics Revenue by Region (2021-2026)
6.2 APAC Biosimilar and Biologics Sales by Type (2021-2026)
6.3 APAC Biosimilar and Biologics Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Biosimilar and Biologics by Country
7.1.1 Europe Biosimilar and Biologics Sales by Country (2021-2026)
7.1.2 Europe Biosimilar and Biologics Revenue by Country (2021-2026)
7.2 Europe Biosimilar and Biologics Sales by Type (2021-2026)
7.3 Europe Biosimilar and Biologics Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Biosimilar and Biologics by Country
8.1.1 Middle East & Africa Biosimilar and Biologics Sales by Country (2021-2026)
8.1.2 Middle East & Africa Biosimilar and Biologics Revenue by Country (2021-2026)
8.2 Middle East & Africa Biosimilar and Biologics Sales by Type (2021-2026)
8.3 Middle East & Africa Biosimilar and Biologics Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biosimilar and Biologics
10.3 Manufacturing Process Analysis of Biosimilar and Biologics
10.4 Industry Chain Structure of Biosimilar and Biologics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biosimilar and Biologics Distributors
11.3 Biosimilar and Biologics Customer
12 WORLD FORECAST REVIEW FOR BIOSIMILAR AND BIOLOGICS BY GEOGRAPHIC REGION
12.1 Global Biosimilar and Biologics Market Size Forecast by Region
12.1.1 Global Biosimilar and Biologics Forecast by Region (2027-2032)
12.1.2 Global Biosimilar and Biologics Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Biosimilar and Biologics Forecast by Type (2027-2032)
12.7 Global Biosimilar and Biologics Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Biosimilar and Biologics Product Portfolios and Specifications
13.1.3 Pfizer Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Roche AG
13.2.1 Roche AG Company Information
13.2.2 Roche AG Biosimilar and Biologics Product Portfolios and Specifications
13.2.3 Roche AG Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Roche AG Main Business Overview
13.2.5 Roche AG Latest Developments
13.3 AbbVie
13.3.1 AbbVie Company Information
13.3.2 AbbVie Biosimilar and Biologics Product Portfolios and Specifications
13.3.3 AbbVie Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 AbbVie Main Business Overview
13.3.5 AbbVie Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG Biosimilar and Biologics Product Portfolios and Specifications
13.4.3 Novartis AG Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Merck
13.5.1 Merck Company Information
13.5.2 Merck Biosimilar and Biologics Product Portfolios and Specifications
13.5.3 Merck Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Merck Main Business Overview
13.5.5 Merck Latest Developments
13.6 Bristol Myers Squibb
13.6.1 Bristol Myers Squibb Company Information
13.6.2 Bristol Myers Squibb Biosimilar and Biologics Product Portfolios and Specifications
13.6.3 Bristol Myers Squibb Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bristol Myers Squibb Main Business Overview
13.6.5 Bristol Myers Squibb Latest Developments
13.7 GSK
13.7.1 GSK Company Information
13.7.2 GSK Biosimilar and Biologics Product Portfolios and Specifications
13.7.3 GSK Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 GSK Main Business Overview
13.7.5 GSK Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Biosimilar and Biologics Product Portfolios and Specifications
13.8.3 AstraZeneca Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 Eli Lilly
13.9.1 Eli Lilly Company Information
13.9.2 Eli Lilly Biosimilar and Biologics Product Portfolios and Specifications
13.9.3 Eli Lilly Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Eli Lilly Main Business Overview
13.9.5 Eli Lilly Latest Developments
13.10 Bayer
13.10.1 Bayer Company Information
13.10.2 Bayer Biosimilar and Biologics Product Portfolios and Specifications
13.10.3 Bayer Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Bayer Main Business Overview
13.10.5 Bayer Latest Developments
13.11 Gilead Sciences
13.11.1 Gilead Sciences Company Information
13.11.2 Gilead Sciences Biosimilar and Biologics Product Portfolios and Specifications
13.11.3 Gilead Sciences Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Gilead Sciences Main Business Overview
13.11.5 Gilead Sciences Latest Developments
13.12 Amgen
13.12.1 Amgen Company Information
13.12.2 Amgen Biosimilar and Biologics Product Portfolios and Specifications
13.12.3 Amgen Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Amgen Main Business Overview
13.12.5 Amgen Latest Developments
13.13 Boehringer Ingelheim
13.13.1 Boehringer Ingelheim Company Information
13.13.2 Boehringer Ingelheim Biosimilar and Biologics Product Portfolios and Specifications
13.13.3 Boehringer Ingelheim Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Boehringer Ingelheim Main Business Overview
13.13.5 Boehringer Ingelheim Latest Developments
13.14 Novo Nordisk
13.14.1 Novo Nordisk Company Information
13.14.2 Novo Nordisk Biosimilar and Biologics Product Portfolios and Specifications
13.14.3 Novo Nordisk Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Novo Nordisk Main Business Overview
13.14.5 Novo Nordisk Latest Developments
13.15 Viatris
13.15.1 Viatris Company Information
13.15.2 Viatris Biosimilar and Biologics Product Portfolios and Specifications
13.15.3 Viatris Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Viatris Main Business Overview
13.15.5 Viatris Latest Developments
13.16 Johnson
13.16.1 Johnson Company Information
13.16.2 Johnson Biosimilar and Biologics Product Portfolios and Specifications
13.16.3 Johnson Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Johnson Main Business Overview
13.16.5 Johnson Latest Developments
13.17 Sanofi Winthrop Industries
13.17.1 Sanofi Winthrop Industries Company Information
13.17.2 Sanofi Winthrop Industries Biosimilar and Biologics Product Portfolios and Specifications
13.17.3 Sanofi Winthrop Industries Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Sanofi Winthrop Industries Main Business Overview
13.17.5 Sanofi Winthrop Industries Latest Developments
13.18 Serum Institute of India
13.18.1 Serum Institute of India Company Information
13.18.2 Serum Institute of India Biosimilar and Biologics Product Portfolios and Specifications
13.18.3 Serum Institute of India Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Serum Institute of India Main Business Overview
13.18.5 Serum Institute of India Latest Developments
13.19 Biocon
13.19.1 Biocon Company Information
13.19.2 Biocon Biosimilar and Biologics Product Portfolios and Specifications
13.19.3 Biocon Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Biocon Main Business Overview
13.19.5 Biocon Latest Developments
13.20 Intas Pharmaceuticals
13.20.1 Intas Pharmaceuticals Company Information
13.20.2 Intas Pharmaceuticals Biosimilar and Biologics Product Portfolios and Specifications
13.20.3 Intas Pharmaceuticals Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Intas Pharmaceuticals Main Business Overview
13.20.5 Intas Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Biosimilar and Biologics Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Biosimilar and Biologics by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Biosimilar and Biologics by Country/Region, 2021, 2025 & 2032
2.2 Biosimilar and Biologics Segment by Type
2.2.1 Monoclonal Antibody
2.2.2 Vaccines
2.2.3 Recombinant Insulin
2.2.4 Growth Factors
2.2.5 Immune Modulators
2.2.6 Fusion Protein
2.2.7 Erythoprotein
2.2.8 Other
2.2.9 Biosimilar and Biologics Sales by Type
2.2.9.1 Global Biosimilar and Biologics Sales Market Share by Type (2021-2026)
2.2.9.2 Global Biosimilar and Biologics Revenue and Market Share by Type (2021-2026)
2.2.9.3 Global Biosimilar and Biologics Sale Price by Type (2021-2026)
2.3 Biosimilar and Biologics Segment by Application
2.3.1 Autoimmune Diseases
2.3.2 Infectious Diseases
2.3.3 Cardiovascular Disorders
2.3.4 Other
2.3.5 Biosimilar and Biologics Sales by Application
2.3.5.1 Global Biosimilar and Biologics Sale Market Share by Application (2021-2026)
2.3.5.2 Global Biosimilar and Biologics Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Biosimilar and Biologics Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Biosimilar and Biologics Breakdown Data by Company
3.1.1 Global Biosimilar and Biologics Annual Sales by Company (2021-2026)
3.1.2 Global Biosimilar and Biologics Sales Market Share by Company (2021-2026)
3.2 Global Biosimilar and Biologics Annual Revenue by Company (2021-2026)
3.2.1 Global Biosimilar and Biologics Revenue by Company (2021-2026)
3.2.2 Global Biosimilar and Biologics Revenue Market Share by Company (2021-2026)
3.3 Global Biosimilar and Biologics Sale Price by Company
3.4 Key Manufacturers Biosimilar and Biologics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biosimilar and Biologics Product Location Distribution
3.4.2 Players Biosimilar and Biologics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BIOSIMILAR AND BIOLOGICS BY GEOGRAPHIC REGION
4.1 World Historic Biosimilar and Biologics Market Size by Geographic Region (2021-2026)
4.1.1 Global Biosimilar and Biologics Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Biosimilar and Biologics Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Biosimilar and Biologics Market Size by Country/Region (2021-2026)
4.2.1 Global Biosimilar and Biologics Annual Sales by Country/Region (2021-2026)
4.2.2 Global Biosimilar and Biologics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Biosimilar and Biologics Sales Growth
4.4 APAC Biosimilar and Biologics Sales Growth
4.5 Europe Biosimilar and Biologics Sales Growth
4.6 Middle East & Africa Biosimilar and Biologics Sales Growth
5 AMERICAS
5.1 Americas Biosimilar and Biologics Sales by Country
5.1.1 Americas Biosimilar and Biologics Sales by Country (2021-2026)
5.1.2 Americas Biosimilar and Biologics Revenue by Country (2021-2026)
5.2 Americas Biosimilar and Biologics Sales by Type (2021-2026)
5.3 Americas Biosimilar and Biologics Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biosimilar and Biologics Sales by Region
6.1.1 APAC Biosimilar and Biologics Sales by Region (2021-2026)
6.1.2 APAC Biosimilar and Biologics Revenue by Region (2021-2026)
6.2 APAC Biosimilar and Biologics Sales by Type (2021-2026)
6.3 APAC Biosimilar and Biologics Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Biosimilar and Biologics by Country
7.1.1 Europe Biosimilar and Biologics Sales by Country (2021-2026)
7.1.2 Europe Biosimilar and Biologics Revenue by Country (2021-2026)
7.2 Europe Biosimilar and Biologics Sales by Type (2021-2026)
7.3 Europe Biosimilar and Biologics Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Biosimilar and Biologics by Country
8.1.1 Middle East & Africa Biosimilar and Biologics Sales by Country (2021-2026)
8.1.2 Middle East & Africa Biosimilar and Biologics Revenue by Country (2021-2026)
8.2 Middle East & Africa Biosimilar and Biologics Sales by Type (2021-2026)
8.3 Middle East & Africa Biosimilar and Biologics Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biosimilar and Biologics
10.3 Manufacturing Process Analysis of Biosimilar and Biologics
10.4 Industry Chain Structure of Biosimilar and Biologics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biosimilar and Biologics Distributors
11.3 Biosimilar and Biologics Customer
12 WORLD FORECAST REVIEW FOR BIOSIMILAR AND BIOLOGICS BY GEOGRAPHIC REGION
12.1 Global Biosimilar and Biologics Market Size Forecast by Region
12.1.1 Global Biosimilar and Biologics Forecast by Region (2027-2032)
12.1.2 Global Biosimilar and Biologics Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Biosimilar and Biologics Forecast by Type (2027-2032)
12.7 Global Biosimilar and Biologics Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Biosimilar and Biologics Product Portfolios and Specifications
13.1.3 Pfizer Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Roche AG
13.2.1 Roche AG Company Information
13.2.2 Roche AG Biosimilar and Biologics Product Portfolios and Specifications
13.2.3 Roche AG Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Roche AG Main Business Overview
13.2.5 Roche AG Latest Developments
13.3 AbbVie
13.3.1 AbbVie Company Information
13.3.2 AbbVie Biosimilar and Biologics Product Portfolios and Specifications
13.3.3 AbbVie Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 AbbVie Main Business Overview
13.3.5 AbbVie Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG Biosimilar and Biologics Product Portfolios and Specifications
13.4.3 Novartis AG Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Merck
13.5.1 Merck Company Information
13.5.2 Merck Biosimilar and Biologics Product Portfolios and Specifications
13.5.3 Merck Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Merck Main Business Overview
13.5.5 Merck Latest Developments
13.6 Bristol Myers Squibb
13.6.1 Bristol Myers Squibb Company Information
13.6.2 Bristol Myers Squibb Biosimilar and Biologics Product Portfolios and Specifications
13.6.3 Bristol Myers Squibb Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bristol Myers Squibb Main Business Overview
13.6.5 Bristol Myers Squibb Latest Developments
13.7 GSK
13.7.1 GSK Company Information
13.7.2 GSK Biosimilar and Biologics Product Portfolios and Specifications
13.7.3 GSK Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 GSK Main Business Overview
13.7.5 GSK Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Biosimilar and Biologics Product Portfolios and Specifications
13.8.3 AstraZeneca Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 Eli Lilly
13.9.1 Eli Lilly Company Information
13.9.2 Eli Lilly Biosimilar and Biologics Product Portfolios and Specifications
13.9.3 Eli Lilly Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Eli Lilly Main Business Overview
13.9.5 Eli Lilly Latest Developments
13.10 Bayer
13.10.1 Bayer Company Information
13.10.2 Bayer Biosimilar and Biologics Product Portfolios and Specifications
13.10.3 Bayer Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Bayer Main Business Overview
13.10.5 Bayer Latest Developments
13.11 Gilead Sciences
13.11.1 Gilead Sciences Company Information
13.11.2 Gilead Sciences Biosimilar and Biologics Product Portfolios and Specifications
13.11.3 Gilead Sciences Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Gilead Sciences Main Business Overview
13.11.5 Gilead Sciences Latest Developments
13.12 Amgen
13.12.1 Amgen Company Information
13.12.2 Amgen Biosimilar and Biologics Product Portfolios and Specifications
13.12.3 Amgen Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Amgen Main Business Overview
13.12.5 Amgen Latest Developments
13.13 Boehringer Ingelheim
13.13.1 Boehringer Ingelheim Company Information
13.13.2 Boehringer Ingelheim Biosimilar and Biologics Product Portfolios and Specifications
13.13.3 Boehringer Ingelheim Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Boehringer Ingelheim Main Business Overview
13.13.5 Boehringer Ingelheim Latest Developments
13.14 Novo Nordisk
13.14.1 Novo Nordisk Company Information
13.14.2 Novo Nordisk Biosimilar and Biologics Product Portfolios and Specifications
13.14.3 Novo Nordisk Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Novo Nordisk Main Business Overview
13.14.5 Novo Nordisk Latest Developments
13.15 Viatris
13.15.1 Viatris Company Information
13.15.2 Viatris Biosimilar and Biologics Product Portfolios and Specifications
13.15.3 Viatris Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Viatris Main Business Overview
13.15.5 Viatris Latest Developments
13.16 Johnson
13.16.1 Johnson Company Information
13.16.2 Johnson Biosimilar and Biologics Product Portfolios and Specifications
13.16.3 Johnson Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Johnson Main Business Overview
13.16.5 Johnson Latest Developments
13.17 Sanofi Winthrop Industries
13.17.1 Sanofi Winthrop Industries Company Information
13.17.2 Sanofi Winthrop Industries Biosimilar and Biologics Product Portfolios and Specifications
13.17.3 Sanofi Winthrop Industries Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Sanofi Winthrop Industries Main Business Overview
13.17.5 Sanofi Winthrop Industries Latest Developments
13.18 Serum Institute of India
13.18.1 Serum Institute of India Company Information
13.18.2 Serum Institute of India Biosimilar and Biologics Product Portfolios and Specifications
13.18.3 Serum Institute of India Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Serum Institute of India Main Business Overview
13.18.5 Serum Institute of India Latest Developments
13.19 Biocon
13.19.1 Biocon Company Information
13.19.2 Biocon Biosimilar and Biologics Product Portfolios and Specifications
13.19.3 Biocon Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Biocon Main Business Overview
13.19.5 Biocon Latest Developments
13.20 Intas Pharmaceuticals
13.20.1 Intas Pharmaceuticals Company Information
13.20.2 Intas Pharmaceuticals Biosimilar and Biologics Product Portfolios and Specifications
13.20.3 Intas Pharmaceuticals Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Intas Pharmaceuticals Main Business Overview
13.20.5 Intas Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Biosimilar and Biologics Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Biosimilar and Biologics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monoclonal Antibody
Table 4. Major Players of Vaccines
Table 5. Major Players of Recombinant Insulin
Table 6. Major Players of Growth Factors
Table 7. Major Players of Immune Modulators
Table 8. Major Players of Fusion Protein
Table 9. Major Players of Erythoprotein
Table 10. Major Players of Other
Table 11. Global Biosimilar and Biologics Sales by Type (2021-2026) & (K Units)
Table 12. Global Biosimilar and Biologics Sales Market Share by Type (2021-2026)
Table 13. Global Biosimilar and Biologics Revenue by Type (2021-2026) & ($ million)
Table 14. Global Biosimilar and Biologics Revenue Market Share by Type (2021-2026)
Table 15. Global Biosimilar and Biologics Sale Price by Type (2021-2026) & (US$/Unit)
Table 16. Global Biosimilar and Biologics Sale by Application (2021-2026) & (K Units)
Table 17. Global Biosimilar and Biologics Sale Market Share by Application (2021-2026)
Table 18. Global Biosimilar and Biologics Revenue by Application (2021-2026) & ($ million)
Table 19. Global Biosimilar and Biologics Revenue Market Share by Application (2021-2026)
Table 20. Global Biosimilar and Biologics Sale Price by Application (2021-2026) & (US$/Unit)
Table 21. Global Biosimilar and Biologics Sales by Company (2021-2026) & (K Units)
Table 22. Global Biosimilar and Biologics Sales Market Share by Company (2021-2026)
Table 23. Global Biosimilar and Biologics Revenue by Company (2021-2026) & ($ millions)
Table 24. Global Biosimilar and Biologics Revenue Market Share by Company (2021-2026)
Table 25. Global Biosimilar and Biologics Sale Price by Company (2021-2026) & (US$/Unit)
Table 26. Key Manufacturers Biosimilar and Biologics Producing Area Distribution and Sales Area
Table 27. Players Biosimilar and Biologics Products Offered
Table 28. Biosimilar and Biologics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 29. New Products and Potential Entrants
Table 30. Market M&A Activity & Strategy
Table 31. Global Biosimilar and Biologics Sales by Geographic Region (2021-2026) & (K Units)
Table 32. Global Biosimilar and Biologics Sales Market Share Geographic Region (2021-2026)
Table 33. Global Biosimilar and Biologics Revenue by Geographic Region (2021-2026) & ($ millions)
Table 34. Global Biosimilar and Biologics Revenue Market Share by Geographic Region (2021-2026)
Table 35. Global Biosimilar and Biologics Sales by Country/Region (2021-2026) & (K Units)
Table 36. Global Biosimilar and Biologics Sales Market Share by Country/Region (2021-2026)
Table 37. Global Biosimilar and Biologics Revenue by Country/Region (2021-2026) & ($ millions)
Table 38. Global Biosimilar and Biologics Revenue Market Share by Country/Region (2021-2026)
Table 39. Americas Biosimilar and Biologics Sales by Country (2021-2026) & (K Units)
Table 40. Americas Biosimilar and Biologics Sales Market Share by Country (2021-2026)
Table 41. Americas Biosimilar and Biologics Revenue by Country (2021-2026) & ($ millions)
Table 42. Americas Biosimilar and Biologics Sales by Type (2021-2026) & (K Units)
Table 43. Americas Biosimilar and Biologics Sales by Application (2021-2026) & (K Units)
Table 44. APAC Biosimilar and Biologics Sales by Region (2021-2026) & (K Units)
Table 45. APAC Biosimilar and Biologics Sales Market Share by Region (2021-2026)
Table 46. APAC Biosimilar and Biologics Revenue by Region (2021-2026) & ($ millions)
Table 47. APAC Biosimilar and Biologics Sales by Type (2021-2026) & (K Units)
Table 48. APAC Biosimilar and Biologics Sales by Application (2021-2026) & (K Units)
Table 49. Europe Biosimilar and Biologics Sales by Country (2021-2026) & (K Units)
Table 50. Europe Biosimilar and Biologics Revenue by Country (2021-2026) & ($ millions)
Table 51. Europe Biosimilar and Biologics Sales by Type (2021-2026) & (K Units)
Table 52. Europe Biosimilar and Biologics Sales by Application (2021-2026) & (K Units)
Table 53. Middle East & Africa Biosimilar and Biologics Sales by Country (2021-2026) & (K Units)
Table 54. Middle East & Africa Biosimilar and Biologics Revenue Market Share by Country (2021-2026)
Table 55. Middle East & Africa Biosimilar and Biologics Sales by Type (2021-2026) & (K Units)
Table 56. Middle East & Africa Biosimilar and Biologics Sales by Application (2021-2026) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Biosimilar and Biologics
Table 58. Key Market Challenges & Risks of Biosimilar and Biologics
Table 59. Key Industry Trends of Biosimilar and Biologics
Table 60. Biosimilar and Biologics Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Biosimilar and Biologics Distributors List
Table 63. Biosimilar and Biologics Customer List
Table 64. Global Biosimilar and Biologics Sales Forecast by Region (2027-2032) & (K Units)
Table 65. Global Biosimilar and Biologics Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Americas Biosimilar and Biologics Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Americas Biosimilar and Biologics Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. APAC Biosimilar and Biologics Sales Forecast by Region (2027-2032) & (K Units)
Table 69. APAC Biosimilar and Biologics Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 70. Europe Biosimilar and Biologics Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Europe Biosimilar and Biologics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Middle East & Africa Biosimilar and Biologics Sales Forecast by Country (2027-2032) & (K Units)
Table 73. Middle East & Africa Biosimilar and Biologics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 74. Global Biosimilar and Biologics Sales Forecast by Type (2027-2032) & (K Units)
Table 75. Global Biosimilar and Biologics Revenue Forecast by Type (2027-2032) & ($ millions)
Table 76. Global Biosimilar and Biologics Sales Forecast by Application (2027-2032) & (K Units)
Table 77. Global Biosimilar and Biologics Revenue Forecast by Application (2027-2032) & ($ millions)
Table 78. Pfizer Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer Biosimilar and Biologics Product Portfolios and Specifications
Table 80. Pfizer Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Roche AG Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 84. Roche AG Biosimilar and Biologics Product Portfolios and Specifications
Table 85. Roche AG Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Roche AG Main Business
Table 87. Roche AG Latest Developments
Table 88. AbbVie Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 89. AbbVie Biosimilar and Biologics Product Portfolios and Specifications
Table 90. AbbVie Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. AbbVie Main Business
Table 92. AbbVie Latest Developments
Table 93. Novartis AG Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 94. Novartis AG Biosimilar and Biologics Product Portfolios and Specifications
Table 95. Novartis AG Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Novartis AG Main Business
Table 97. Novartis AG Latest Developments
Table 98. Merck Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 99. Merck Biosimilar and Biologics Product Portfolios and Specifications
Table 100. Merck Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Merck Main Business
Table 102. Merck Latest Developments
Table 103. Bristol Myers Squibb Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 104. Bristol Myers Squibb Biosimilar and Biologics Product Portfolios and Specifications
Table 105. Bristol Myers Squibb Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Bristol Myers Squibb Main Business
Table 107. Bristol Myers Squibb Latest Developments
Table 108. GSK Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 109. GSK Biosimilar and Biologics Product Portfolios and Specifications
Table 110. GSK Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. GSK Main Business
Table 112. GSK Latest Developments
Table 113. AstraZeneca Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 114. AstraZeneca Biosimilar and Biologics Product Portfolios and Specifications
Table 115. AstraZeneca Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. AstraZeneca Main Business
Table 117. AstraZeneca Latest Developments
Table 118. Eli Lilly Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 119. Eli Lilly Biosimilar and Biologics Product Portfolios and Specifications
Table 120. Eli Lilly Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Eli Lilly Main Business
Table 122. Eli Lilly Latest Developments
Table 123. Bayer Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 124. Bayer Biosimilar and Biologics Product Portfolios and Specifications
Table 125. Bayer Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Bayer Main Business
Table 127. Bayer Latest Developments
Table 128. Gilead Sciences Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 129. Gilead Sciences Biosimilar and Biologics Product Portfolios and Specifications
Table 130. Gilead Sciences Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Gilead Sciences Main Business
Table 132. Gilead Sciences Latest Developments
Table 133. Amgen Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 134. Amgen Biosimilar and Biologics Product Portfolios and Specifications
Table 135. Amgen Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Amgen Main Business
Table 137. Amgen Latest Developments
Table 138. Boehringer Ingelheim Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 139. Boehringer Ingelheim Biosimilar and Biologics Product Portfolios and Specifications
Table 140. Boehringer Ingelheim Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Boehringer Ingelheim Main Business
Table 142. Boehringer Ingelheim Latest Developments
Table 143. Novo Nordisk Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 144. Novo Nordisk Biosimilar and Biologics Product Portfolios and Specifications
Table 145. Novo Nordisk Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Novo Nordisk Main Business
Table 147. Novo Nordisk Latest Developments
Table 148. Viatris Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 149. Viatris Biosimilar and Biologics Product Portfolios and Specifications
Table 150. Viatris Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Viatris Main Business
Table 152. Viatris Latest Developments
Table 153. Johnson Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 154. Johnson Biosimilar and Biologics Product Portfolios and Specifications
Table 155. Johnson Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Johnson Main Business
Table 157. Johnson Latest Developments
Table 158. Sanofi Winthrop Industries Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 159. Sanofi Winthrop Industries Biosimilar and Biologics Product Portfolios and Specifications
Table 160. Sanofi Winthrop Industries Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Sanofi Winthrop Industries Main Business
Table 162. Sanofi Winthrop Industries Latest Developments
Table 163. Serum Institute of India Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 164. Serum Institute of India Biosimilar and Biologics Product Portfolios and Specifications
Table 165. Serum Institute of India Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. Serum Institute of India Main Business
Table 167. Serum Institute of India Latest Developments
Table 168. Biocon Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 169. Biocon Biosimilar and Biologics Product Portfolios and Specifications
Table 170. Biocon Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 171. Biocon Main Business
Table 172. Biocon Latest Developments
Table 173. Intas Pharmaceuticals Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 174. Intas Pharmaceuticals Biosimilar and Biologics Product Portfolios and Specifications
Table 175. Intas Pharmaceuticals Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 176. Intas Pharmaceuticals Main Business
Table 177. Intas Pharmaceuticals Latest Developments
Table 1. Biosimilar and Biologics Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Biosimilar and Biologics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Monoclonal Antibody
Table 4. Major Players of Vaccines
Table 5. Major Players of Recombinant Insulin
Table 6. Major Players of Growth Factors
Table 7. Major Players of Immune Modulators
Table 8. Major Players of Fusion Protein
Table 9. Major Players of Erythoprotein
Table 10. Major Players of Other
Table 11. Global Biosimilar and Biologics Sales by Type (2021-2026) & (K Units)
Table 12. Global Biosimilar and Biologics Sales Market Share by Type (2021-2026)
Table 13. Global Biosimilar and Biologics Revenue by Type (2021-2026) & ($ million)
Table 14. Global Biosimilar and Biologics Revenue Market Share by Type (2021-2026)
Table 15. Global Biosimilar and Biologics Sale Price by Type (2021-2026) & (US$/Unit)
Table 16. Global Biosimilar and Biologics Sale by Application (2021-2026) & (K Units)
Table 17. Global Biosimilar and Biologics Sale Market Share by Application (2021-2026)
Table 18. Global Biosimilar and Biologics Revenue by Application (2021-2026) & ($ million)
Table 19. Global Biosimilar and Biologics Revenue Market Share by Application (2021-2026)
Table 20. Global Biosimilar and Biologics Sale Price by Application (2021-2026) & (US$/Unit)
Table 21. Global Biosimilar and Biologics Sales by Company (2021-2026) & (K Units)
Table 22. Global Biosimilar and Biologics Sales Market Share by Company (2021-2026)
Table 23. Global Biosimilar and Biologics Revenue by Company (2021-2026) & ($ millions)
Table 24. Global Biosimilar and Biologics Revenue Market Share by Company (2021-2026)
Table 25. Global Biosimilar and Biologics Sale Price by Company (2021-2026) & (US$/Unit)
Table 26. Key Manufacturers Biosimilar and Biologics Producing Area Distribution and Sales Area
Table 27. Players Biosimilar and Biologics Products Offered
Table 28. Biosimilar and Biologics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 29. New Products and Potential Entrants
Table 30. Market M&A Activity & Strategy
Table 31. Global Biosimilar and Biologics Sales by Geographic Region (2021-2026) & (K Units)
Table 32. Global Biosimilar and Biologics Sales Market Share Geographic Region (2021-2026)
Table 33. Global Biosimilar and Biologics Revenue by Geographic Region (2021-2026) & ($ millions)
Table 34. Global Biosimilar and Biologics Revenue Market Share by Geographic Region (2021-2026)
Table 35. Global Biosimilar and Biologics Sales by Country/Region (2021-2026) & (K Units)
Table 36. Global Biosimilar and Biologics Sales Market Share by Country/Region (2021-2026)
Table 37. Global Biosimilar and Biologics Revenue by Country/Region (2021-2026) & ($ millions)
Table 38. Global Biosimilar and Biologics Revenue Market Share by Country/Region (2021-2026)
Table 39. Americas Biosimilar and Biologics Sales by Country (2021-2026) & (K Units)
Table 40. Americas Biosimilar and Biologics Sales Market Share by Country (2021-2026)
Table 41. Americas Biosimilar and Biologics Revenue by Country (2021-2026) & ($ millions)
Table 42. Americas Biosimilar and Biologics Sales by Type (2021-2026) & (K Units)
Table 43. Americas Biosimilar and Biologics Sales by Application (2021-2026) & (K Units)
Table 44. APAC Biosimilar and Biologics Sales by Region (2021-2026) & (K Units)
Table 45. APAC Biosimilar and Biologics Sales Market Share by Region (2021-2026)
Table 46. APAC Biosimilar and Biologics Revenue by Region (2021-2026) & ($ millions)
Table 47. APAC Biosimilar and Biologics Sales by Type (2021-2026) & (K Units)
Table 48. APAC Biosimilar and Biologics Sales by Application (2021-2026) & (K Units)
Table 49. Europe Biosimilar and Biologics Sales by Country (2021-2026) & (K Units)
Table 50. Europe Biosimilar and Biologics Revenue by Country (2021-2026) & ($ millions)
Table 51. Europe Biosimilar and Biologics Sales by Type (2021-2026) & (K Units)
Table 52. Europe Biosimilar and Biologics Sales by Application (2021-2026) & (K Units)
Table 53. Middle East & Africa Biosimilar and Biologics Sales by Country (2021-2026) & (K Units)
Table 54. Middle East & Africa Biosimilar and Biologics Revenue Market Share by Country (2021-2026)
Table 55. Middle East & Africa Biosimilar and Biologics Sales by Type (2021-2026) & (K Units)
Table 56. Middle East & Africa Biosimilar and Biologics Sales by Application (2021-2026) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Biosimilar and Biologics
Table 58. Key Market Challenges & Risks of Biosimilar and Biologics
Table 59. Key Industry Trends of Biosimilar and Biologics
Table 60. Biosimilar and Biologics Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Biosimilar and Biologics Distributors List
Table 63. Biosimilar and Biologics Customer List
Table 64. Global Biosimilar and Biologics Sales Forecast by Region (2027-2032) & (K Units)
Table 65. Global Biosimilar and Biologics Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Americas Biosimilar and Biologics Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Americas Biosimilar and Biologics Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. APAC Biosimilar and Biologics Sales Forecast by Region (2027-2032) & (K Units)
Table 69. APAC Biosimilar and Biologics Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 70. Europe Biosimilar and Biologics Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Europe Biosimilar and Biologics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Middle East & Africa Biosimilar and Biologics Sales Forecast by Country (2027-2032) & (K Units)
Table 73. Middle East & Africa Biosimilar and Biologics Revenue Forecast by Country (2027-2032) & ($ millions)
Table 74. Global Biosimilar and Biologics Sales Forecast by Type (2027-2032) & (K Units)
Table 75. Global Biosimilar and Biologics Revenue Forecast by Type (2027-2032) & ($ millions)
Table 76. Global Biosimilar and Biologics Sales Forecast by Application (2027-2032) & (K Units)
Table 77. Global Biosimilar and Biologics Revenue Forecast by Application (2027-2032) & ($ millions)
Table 78. Pfizer Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer Biosimilar and Biologics Product Portfolios and Specifications
Table 80. Pfizer Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Roche AG Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 84. Roche AG Biosimilar and Biologics Product Portfolios and Specifications
Table 85. Roche AG Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Roche AG Main Business
Table 87. Roche AG Latest Developments
Table 88. AbbVie Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 89. AbbVie Biosimilar and Biologics Product Portfolios and Specifications
Table 90. AbbVie Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. AbbVie Main Business
Table 92. AbbVie Latest Developments
Table 93. Novartis AG Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 94. Novartis AG Biosimilar and Biologics Product Portfolios and Specifications
Table 95. Novartis AG Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Novartis AG Main Business
Table 97. Novartis AG Latest Developments
Table 98. Merck Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 99. Merck Biosimilar and Biologics Product Portfolios and Specifications
Table 100. Merck Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Merck Main Business
Table 102. Merck Latest Developments
Table 103. Bristol Myers Squibb Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 104. Bristol Myers Squibb Biosimilar and Biologics Product Portfolios and Specifications
Table 105. Bristol Myers Squibb Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Bristol Myers Squibb Main Business
Table 107. Bristol Myers Squibb Latest Developments
Table 108. GSK Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 109. GSK Biosimilar and Biologics Product Portfolios and Specifications
Table 110. GSK Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. GSK Main Business
Table 112. GSK Latest Developments
Table 113. AstraZeneca Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 114. AstraZeneca Biosimilar and Biologics Product Portfolios and Specifications
Table 115. AstraZeneca Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. AstraZeneca Main Business
Table 117. AstraZeneca Latest Developments
Table 118. Eli Lilly Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 119. Eli Lilly Biosimilar and Biologics Product Portfolios and Specifications
Table 120. Eli Lilly Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Eli Lilly Main Business
Table 122. Eli Lilly Latest Developments
Table 123. Bayer Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 124. Bayer Biosimilar and Biologics Product Portfolios and Specifications
Table 125. Bayer Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Bayer Main Business
Table 127. Bayer Latest Developments
Table 128. Gilead Sciences Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 129. Gilead Sciences Biosimilar and Biologics Product Portfolios and Specifications
Table 130. Gilead Sciences Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Gilead Sciences Main Business
Table 132. Gilead Sciences Latest Developments
Table 133. Amgen Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 134. Amgen Biosimilar and Biologics Product Portfolios and Specifications
Table 135. Amgen Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Amgen Main Business
Table 137. Amgen Latest Developments
Table 138. Boehringer Ingelheim Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 139. Boehringer Ingelheim Biosimilar and Biologics Product Portfolios and Specifications
Table 140. Boehringer Ingelheim Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Boehringer Ingelheim Main Business
Table 142. Boehringer Ingelheim Latest Developments
Table 143. Novo Nordisk Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 144. Novo Nordisk Biosimilar and Biologics Product Portfolios and Specifications
Table 145. Novo Nordisk Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Novo Nordisk Main Business
Table 147. Novo Nordisk Latest Developments
Table 148. Viatris Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 149. Viatris Biosimilar and Biologics Product Portfolios and Specifications
Table 150. Viatris Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Viatris Main Business
Table 152. Viatris Latest Developments
Table 153. Johnson Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 154. Johnson Biosimilar and Biologics Product Portfolios and Specifications
Table 155. Johnson Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Johnson Main Business
Table 157. Johnson Latest Developments
Table 158. Sanofi Winthrop Industries Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 159. Sanofi Winthrop Industries Biosimilar and Biologics Product Portfolios and Specifications
Table 160. Sanofi Winthrop Industries Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Sanofi Winthrop Industries Main Business
Table 162. Sanofi Winthrop Industries Latest Developments
Table 163. Serum Institute of India Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 164. Serum Institute of India Biosimilar and Biologics Product Portfolios and Specifications
Table 165. Serum Institute of India Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. Serum Institute of India Main Business
Table 167. Serum Institute of India Latest Developments
Table 168. Biocon Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 169. Biocon Biosimilar and Biologics Product Portfolios and Specifications
Table 170. Biocon Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 171. Biocon Main Business
Table 172. Biocon Latest Developments
Table 173. Intas Pharmaceuticals Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 174. Intas Pharmaceuticals Biosimilar and Biologics Product Portfolios and Specifications
Table 175. Intas Pharmaceuticals Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 176. Intas Pharmaceuticals Main Business
Table 177. Intas Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Biosimilar and Biologics
Figure 2. Biosimilar and Biologics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biosimilar and Biologics Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Biosimilar and Biologics Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Biosimilar and Biologics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Biosimilar and Biologics Sales Market Share by Country/Region (2025)
Figure 10. Biosimilar and Biologics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Monoclonal Antibody
Figure 12. Product Picture of Vaccines
Figure 13. Product Picture of Recombinant Insulin
Figure 14. Product Picture of Growth Factors
Figure 15. Product Picture of Immune Modulators
Figure 16. Product Picture of Fusion Protein
Figure 17. Product Picture of Erythoprotein
Figure 18. Product Picture of Other
Figure 19. Global Biosimilar and Biologics Sales Market Share by Type in 2026
Figure 20. Global Biosimilar and Biologics Revenue Market Share by Type (2021-2026)
Figure 21. Biosimilar and Biologics Consumed in Autoimmune Diseases
Figure 22. Global Biosimilar and Biologics Market: Autoimmune Diseases (2021-2026) & (K Units)
Figure 23. Biosimilar and Biologics Consumed in Infectious Diseases
Figure 24. Global Biosimilar and Biologics Market: Infectious Diseases (2021-2026) & (K Units)
Figure 25. Biosimilar and Biologics Consumed in Cardiovascular Disorders
Figure 26. Global Biosimilar and Biologics Market: Cardiovascular Disorders (2021-2026) & (K Units)
Figure 27. Biosimilar and Biologics Consumed in Other
Figure 28. Global Biosimilar and Biologics Market: Other (2021-2026) & (K Units)
Figure 29. Global Biosimilar and Biologics Sale Market Share by Application (2025)
Figure 30. Global Biosimilar and Biologics Revenue Market Share by Application in 2026
Figure 31. Biosimilar and Biologics Sales by Company in 2026 (K Units)
Figure 32. Global Biosimilar and Biologics Sales Market Share by Company in 2026
Figure 33. Biosimilar and Biologics Revenue by Company in 2026 ($ millions)
Figure 34. Global Biosimilar and Biologics Revenue Market Share by Company in 2026
Figure 35. Global Biosimilar and Biologics Sales Market Share by Geographic Region (2021-2026)
Figure 36. Global Biosimilar and Biologics Revenue Market Share by Geographic Region in 2026
Figure 37. Americas Biosimilar and Biologics Sales 2021-2026 (K Units)
Figure 38. Americas Biosimilar and Biologics Revenue 2021-2026 ($ millions)
Figure 39. APAC Biosimilar and Biologics Sales 2021-2026 (K Units)
Figure 40. APAC Biosimilar and Biologics Revenue 2021-2026 ($ millions)
Figure 41. Europe Biosimilar and Biologics Sales 2021-2026 (K Units)
Figure 42. Europe Biosimilar and Biologics Revenue 2021-2026 ($ millions)
Figure 43. Middle East & Africa Biosimilar and Biologics Sales 2021-2026 (K Units)
Figure 44. Middle East & Africa Biosimilar and Biologics Revenue 2021-2026 ($ millions)
Figure 45. Americas Biosimilar and Biologics Sales Market Share by Country in 2026
Figure 46. Americas Biosimilar and Biologics Revenue Market Share by Country (2021-2026)
Figure 47. Americas Biosimilar and Biologics Sales Market Share by Type (2021-2026)
Figure 48. Americas Biosimilar and Biologics Sales Market Share by Application (2021-2026)
Figure 49. United States Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 50. Canada Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 51. Mexico Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 52. Brazil Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 53. APAC Biosimilar and Biologics Sales Market Share by Region in 2026
Figure 54. APAC Biosimilar and Biologics Revenue Market Share by Region (2021-2026)
Figure 55. APAC Biosimilar and Biologics Sales Market Share by Type (2021-2026)
Figure 56. APAC Biosimilar and Biologics Sales Market Share by Application (2021-2026)
Figure 57. China Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 58. Japan Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 59. South Korea Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 60. Southeast Asia Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 61. India Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 62. Australia Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 63. China Taiwan Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 64. Europe Biosimilar and Biologics Sales Market Share by Country in 2026
Figure 65. Europe Biosimilar and Biologics Revenue Market Share by Country (2021-2026)
Figure 66. Europe Biosimilar and Biologics Sales Market Share by Type (2021-2026)
Figure 67. Europe Biosimilar and Biologics Sales Market Share by Application (2021-2026)
Figure 68. Germany Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 69. France Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 70. UK Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 71. Italy Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 72. Russia Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 73. Middle East & Africa Biosimilar and Biologics Sales Market Share by Country (2021-2026)
Figure 74. Middle East & Africa Biosimilar and Biologics Sales Market Share by Type (2021-2026)
Figure 75. Middle East & Africa Biosimilar and Biologics Sales Market Share by Application (2021-2026)
Figure 76. Egypt Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 77. South Africa Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 78. Israel Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 79. Turkey Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 80. GCC Countries Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 81. Manufacturing Cost Structure Analysis of Biosimilar and Biologics in 2026
Figure 82. Manufacturing Process Analysis of Biosimilar and Biologics
Figure 83. Industry Chain Structure of Biosimilar and Biologics
Figure 84. Channels of Distribution
Figure 85. Global Biosimilar and Biologics Sales Market Forecast by Region (2027-2032)
Figure 86. Global Biosimilar and Biologics Revenue Market Share Forecast by Region (2027-2032)
Figure 87. Global Biosimilar and Biologics Sales Market Share Forecast by Type (2027-2032)
Figure 88. Global Biosimilar and Biologics Revenue Market Share Forecast by Type (2027-2032)
Figure 89. Global Biosimilar and Biologics Sales Market Share Forecast by Application (2027-2032)
Figure 90. Global Biosimilar and Biologics Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Biosimilar and Biologics
Figure 2. Biosimilar and Biologics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biosimilar and Biologics Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Biosimilar and Biologics Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Biosimilar and Biologics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Biosimilar and Biologics Sales Market Share by Country/Region (2025)
Figure 10. Biosimilar and Biologics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Monoclonal Antibody
Figure 12. Product Picture of Vaccines
Figure 13. Product Picture of Recombinant Insulin
Figure 14. Product Picture of Growth Factors
Figure 15. Product Picture of Immune Modulators
Figure 16. Product Picture of Fusion Protein
Figure 17. Product Picture of Erythoprotein
Figure 18. Product Picture of Other
Figure 19. Global Biosimilar and Biologics Sales Market Share by Type in 2026
Figure 20. Global Biosimilar and Biologics Revenue Market Share by Type (2021-2026)
Figure 21. Biosimilar and Biologics Consumed in Autoimmune Diseases
Figure 22. Global Biosimilar and Biologics Market: Autoimmune Diseases (2021-2026) & (K Units)
Figure 23. Biosimilar and Biologics Consumed in Infectious Diseases
Figure 24. Global Biosimilar and Biologics Market: Infectious Diseases (2021-2026) & (K Units)
Figure 25. Biosimilar and Biologics Consumed in Cardiovascular Disorders
Figure 26. Global Biosimilar and Biologics Market: Cardiovascular Disorders (2021-2026) & (K Units)
Figure 27. Biosimilar and Biologics Consumed in Other
Figure 28. Global Biosimilar and Biologics Market: Other (2021-2026) & (K Units)
Figure 29. Global Biosimilar and Biologics Sale Market Share by Application (2025)
Figure 30. Global Biosimilar and Biologics Revenue Market Share by Application in 2026
Figure 31. Biosimilar and Biologics Sales by Company in 2026 (K Units)
Figure 32. Global Biosimilar and Biologics Sales Market Share by Company in 2026
Figure 33. Biosimilar and Biologics Revenue by Company in 2026 ($ millions)
Figure 34. Global Biosimilar and Biologics Revenue Market Share by Company in 2026
Figure 35. Global Biosimilar and Biologics Sales Market Share by Geographic Region (2021-2026)
Figure 36. Global Biosimilar and Biologics Revenue Market Share by Geographic Region in 2026
Figure 37. Americas Biosimilar and Biologics Sales 2021-2026 (K Units)
Figure 38. Americas Biosimilar and Biologics Revenue 2021-2026 ($ millions)
Figure 39. APAC Biosimilar and Biologics Sales 2021-2026 (K Units)
Figure 40. APAC Biosimilar and Biologics Revenue 2021-2026 ($ millions)
Figure 41. Europe Biosimilar and Biologics Sales 2021-2026 (K Units)
Figure 42. Europe Biosimilar and Biologics Revenue 2021-2026 ($ millions)
Figure 43. Middle East & Africa Biosimilar and Biologics Sales 2021-2026 (K Units)
Figure 44. Middle East & Africa Biosimilar and Biologics Revenue 2021-2026 ($ millions)
Figure 45. Americas Biosimilar and Biologics Sales Market Share by Country in 2026
Figure 46. Americas Biosimilar and Biologics Revenue Market Share by Country (2021-2026)
Figure 47. Americas Biosimilar and Biologics Sales Market Share by Type (2021-2026)
Figure 48. Americas Biosimilar and Biologics Sales Market Share by Application (2021-2026)
Figure 49. United States Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 50. Canada Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 51. Mexico Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 52. Brazil Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 53. APAC Biosimilar and Biologics Sales Market Share by Region in 2026
Figure 54. APAC Biosimilar and Biologics Revenue Market Share by Region (2021-2026)
Figure 55. APAC Biosimilar and Biologics Sales Market Share by Type (2021-2026)
Figure 56. APAC Biosimilar and Biologics Sales Market Share by Application (2021-2026)
Figure 57. China Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 58. Japan Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 59. South Korea Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 60. Southeast Asia Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 61. India Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 62. Australia Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 63. China Taiwan Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 64. Europe Biosimilar and Biologics Sales Market Share by Country in 2026
Figure 65. Europe Biosimilar and Biologics Revenue Market Share by Country (2021-2026)
Figure 66. Europe Biosimilar and Biologics Sales Market Share by Type (2021-2026)
Figure 67. Europe Biosimilar and Biologics Sales Market Share by Application (2021-2026)
Figure 68. Germany Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 69. France Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 70. UK Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 71. Italy Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 72. Russia Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 73. Middle East & Africa Biosimilar and Biologics Sales Market Share by Country (2021-2026)
Figure 74. Middle East & Africa Biosimilar and Biologics Sales Market Share by Type (2021-2026)
Figure 75. Middle East & Africa Biosimilar and Biologics Sales Market Share by Application (2021-2026)
Figure 76. Egypt Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 77. South Africa Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 78. Israel Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 79. Turkey Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 80. GCC Countries Biosimilar and Biologics Revenue Growth 2021-2026 ($ millions)
Figure 81. Manufacturing Cost Structure Analysis of Biosimilar and Biologics in 2026
Figure 82. Manufacturing Process Analysis of Biosimilar and Biologics
Figure 83. Industry Chain Structure of Biosimilar and Biologics
Figure 84. Channels of Distribution
Figure 85. Global Biosimilar and Biologics Sales Market Forecast by Region (2027-2032)
Figure 86. Global Biosimilar and Biologics Revenue Market Share Forecast by Region (2027-2032)
Figure 87. Global Biosimilar and Biologics Sales Market Share Forecast by Type (2027-2032)
Figure 88. Global Biosimilar and Biologics Revenue Market Share Forecast by Type (2027-2032)
Figure 89. Global Biosimilar and Biologics Sales Market Share Forecast by Application (2027-2032)
Figure 90. Global Biosimilar and Biologics Revenue Market Share Forecast by Application (2027-2032)
